Nearly a dozen state treasurers are asking Gilead Sciences (GILD) to lower the price of its experimental remdesivir treatment for Covid-19, arguing the company is attempting to market an “old drug at prices that are disconnected from economic reality.”

In a letter to Gilead chief executive Daniel O’Day, the state officials cautioned that Gilead should not take “financial advantage” of the pandemic to pursue “unreasonable profits” because it “sets a dangerous precedent for future treatments in development.” The letter was sent by treasurers in Ohio, Pennsylvania, Nevada, Maine, Iowa, Oregon, Colorado, Wisconsin, Texas, Rhode Island, and Massachusetts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Very interesting to see that California, by far the state with the largest number of cases, is not one of the States. Perhaps Governor Newsome being astute nd smart enough and with Gilead located in CA, have already negotiated or is actually negotaiating for a CA only price for remdesivir.

    IMHO that would be a much better approach. It actually has a precedent a while back with GIlead’s HCV drugs (Harvoni and Epclusa). I also believe for the HIV meds, Gilead also negotiatee with each State’s Medicaid for a state specific price within the ADAP (Aids Drug Assistance Program).

    art B of the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Public Law 111-87) provides grants to U.S. states and territories. The AIDS Drug Assistance Program (ADAP) is a state and territory-administered program authorized under Part B that provides FDA-approved medications to low-income people living with HIV who have limited or no health coverage from private insurance, Medicaid, or Medicare. ADAP funds may also be used to purchase health insurance for eligible clients and for services that enhance access to, adherence to, and monitoring of drug treatments.

    https://hab.hrsa.gov/about-ryan-white-hivaids-program/part-b-aids-drug-assistance-program

  • “The missive is also the latest complaint by state officials over pricing for the Gilead drug, which the Food and Drug Administration last May authorized for emergency use to combat the virus.”

    Although this pandemic sure feels like forever, this was only a few months ago 🙁

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy